TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06001320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir 480 mg once daily
Description: We will test the study hypothesis in a single center, matched (1:1 fashion) pilot study of Letermovir 480 mg once daily versus historically matched AA kidney transplant recipients who received valganciclovir. We will enroll 30 AA patients over a 12-month period into the Letermovir group and compare outcomes to a historical group of 30 AA kidney transplant recipients who have received valganciclovir prophylaxis (1:1 fashion), for a total of 60 patients. We will attempt to match patients on Letermovir to the historical patients who received valganciclovir, based on age, kidney Donor profile index and the presence of panel of reactive antibodies.

Intervention type: OTHER
Group type: OTHER
Intervention: Historical/Control
Description: The control study group will include high-risk African American kidney transplant recipients cared for with Valganciclovir in the 5 years prior to the enrollment start for the study group. This time frame is based upon the current volume of transplants done at VCU. On average 30 liver and/or kidney transplants are done per month. Thus, 5 years should be an adequate time frame to mine enough number of participants to answer our primary research hypothesis.
Study: NCT05462613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: - Regorafenib will be administered 3 weeks out of 4 for two months or unacceptable toxicity.~* For the first cycle: regorafenib will be administered according to the REDOS schedule (80 mg daily for week 1, 120 mg daily for week 2 and 160 mg daily for the third week of the first cycle).~* For the second cycle: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapies
Description: * Capecitabine: 625mg/m²/orally twice daily continuously during the first two months~* Cyclophosphamide: 50 mg per os, daily, for two months
Study: NCT06413615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA022-BB05
Description: Monoclonal antibody-drug conjugate for injection
Study: NCT05462613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 75 mg orally and daily during two months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/Kg every 2 weeks according to investigator practice, until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/Kg every 2 weeks according to investigator practice, until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI or FOLFOX
Description: every 2 weeks according to investigator practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI or FOLFOX
Description: every 2 weeks according to investigator practice
Study: NCT05768139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STX-478
Description: STX-478 is a mutant-selective PI3Kα inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STX-478
Description: STX-478 is a mutant-selective PI3Kα inhibitor
Study: NCT06413615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA022-BB05
Description: Monoclonal antibody-drug conjugate for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA022-BB05
Description: Monoclonal antibody-drug conjugate for injection
Study: NCT05054933

Intervention type: OTHER
Group type: OTHER
Intervention: ultrasound capsule endoscopy
Description: Healthy volunteers or patients with suspected esophageal disease will be enrolled to take ultrasound capsule endoscopy examination followed by conventional endoscopic ultrasound examination within 2 weeks.
Study: NCT05647252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Whole Body and nasal decolonization with octenidin (Octenisan Set)
Description: Octenidin body lotion once a day during the five consecutive days preceding the elective orthopedic surgery, including for the hair.~Octenidin nasal creme 2-3 times a day in both nasal orifices during the same period
Study: NCT06047431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706H
Description: QL1706H is the subcutaneousely administered formulation of QL1706, it contains two unique monoclonal antibodies.
Study: NCT04921722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Percutaneous sirolimus
Description: We compare topical and oral use of sirolimus in the treatment of superficial complicted vascular anomalies. In experimental group, we administrate percutaneous sirolimus. Drop 5 ml of sirolimus oral solution and 5 g of dressing into the mixed bottle. Apply mixed gel of topical sirolimus to affected area. Use it twice a day for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral sirolimus
Description: We compare topical and oral use of sirolimus in the treatment of superficial complicted vascular anomalies. In active comparator group, we administrate oral sirolimus. Oral dose of sirolimus is calculated according to body surface area. Take it twice a day for 6 months. Maintain the blood concentration of sirolimus at 5-15ng/ml.
Study: NCT04691323

Intervention type: OTHER
Group type: OTHER
Intervention: HU-Go app
Description: A novel multifunctional mobile app (HU-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
Study: NCT04885244

Intervention type: PROCEDURE
Intervention: Index or spine revision surgery for complex adult spinal deformity
Description: Surgical interventions will be patient specified by treating surgeon.
Study: NCT04591314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: The intervention by neurofeedback (NF) will consist in providing the subjects with a feedback on their EEG Theta / Beta activity in real time Each subject will perform 8 sessions of neurofeedback (1h30 / session, 40 min of effective training by neurofeedback) at an average rate of 1 to 2 sessions per week.
Study: NCT05027646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sancuso - Part 1
Description: Part 1 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sancuso - Part 2
Description: Part 2 - A Potent anti-emetic and highly selective antagonist of 5-HT3 receptors.
Study: NCT06242665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low UPF Meals (Study Provided)
Description: Meals provided through delivery service

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low UPF Nutritional Guidance
Description: Self-guided instructions from study team.
Study: NCT04789733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tight pressure management
Description: Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg, delayed resumption of chronic antihypertensive medications, and a target ward MAP ≥80 mmHg (tight pressure management)

Intervention type: OTHER
Group type: OTHER
Intervention: Routine pressure management
Description: Routine intraoperative blood pressure management and immediate restart of antihypertensive medications.
Study: NCT04408924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study: NCT05319574

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic body radiation therapy delivered with a fixed dose (8Gy) in 3 daily fractions 1-7 days before the first cycle of immunochemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg q3w for two cycles administrated concurrently with chemotherapy
Study: NCT05647252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire for study participants immediately after the decolonization
Description: A questionnaire in GErman language will be handed out to decolonized patients with five questions: Practical difficulties of decolonization, the completeness of scheduled decolonization actions, all adverse events during decolonization and surgery, and two questions regarding the comprehension of the science (indication for decolonization, potential benefit expected in the individual case).~The questionnaire is handmade and validated by the Investigators.
Study: NCT05721729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mizagliflozin
Description: Encapsulated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mizagliflozin
Description: Encapsulated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Encapsulated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Encapsulated
Study: NCT06304896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol 6.25 mg oral tablets. Prescribed: Twice daily PO with 200 mL of water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril 2.5 mg oral capsules. Prescribed: Once daily PO with 200 mL of water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 20 mg oral tablets. Prescribed: Once daily PO with 200 mL of water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine 0.6 mg oral tablets/capsules. Prescribed: Once daily PO with 200 mL of water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsules. Prescribed: Once daily PO with 200 mL of water.
Study: NCT05768139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib
Study: NCT06642935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Totally implantable cochlear Implant
Description: Totally implantable cochlear Implant
Study: NCT05703672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate
Description: 0.5 mg once daily for days 1-3, 0.5mg twice daily for days 4-7 and 1.0 mg twice daily from day 8 through week 12.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One pill (white) once daily for days 1-3, one pill (white) twice daily for days 4-7 and one pill (blue) twice daily from day 8 through week 12.

Intervention type: OTHER
Group type: OTHER
Intervention: Electronic cigarette
Description: Nicotine salt pod based e-cigarette in 5% nicotine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electronic cigarette
Description: Nicotine salt pod based e-cigarette in 5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic cigarette
Description: Nicotine salt pod based e-cigarette in 5% nicotine
Study: NCT04632303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Palliative Care
Description: Baseline palliative care visit Palliative care visits/calls at least every 4 weeks throughout life and additionally upon request Referral to exercise training Referral to nutritional specialist
Study: NCT05851326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Sonodyn
Description: Sonodyn emits ultrasound, electrical and magnetic stimulation signals with a pre-defined, fixed set of parameters for each of the independently operated power sources.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Non-functional Sonodyn device that cannot convey any energy signals to the device output, however, looks and behaves fully identical as the active Sonodyn device.
Study: NCT05114538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reciprocal Imitation Training
Description: RIT is a relatively straightforward, brief NDBI. It employs four simple strategies to target motor imitation and IJA during play: (1) contingent imitation of the child's verbal and nonverbal behavior, (2) linguistic mapping, (3) direct elicitation of object and gesture imitation following the child's interest, and (4) contingent reinforcement. It has been used at low intensities (e.g., 1-3 hours per week) over short periods of time (e.g., 10-12 weeks) to produce robust changes in pivotal skills. It is easy to learn and can be implemented with fidelity by undergraduate-level therapists with limited backgrounds in ASD, as well as by parents and siblings.
Study: NCT05373940

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICD implantation
Description: This group will undergo an ICD implantation (type and manufacturer at the discretion of the local investigator) in addition to heart failure medical therapy optimization.~Patients of the HFOT+ICD group will be scheduled for ICD implantation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No ICD implantation
Description: Patients of the HFOT alone group will not undergo ICD implantation (except if they develop sustained ventricular arrhythmias and fulfil for secondary prevention ICD implantation), and continue with medical therapy optimization only.
Study: NCT06424483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Awareness, Courage, and Love Group Psychotherapy
Description: Awareness, Courage, and Love (ACL) groups are an outgrowth of functional analytic psychotherapy, which is an empirically-based behavioural therapy that emphasizes the principle of positive reinforcement within relationships (Holman et al., 2017; Kanter et al., 2010; Kohlenberg \& Tsai, 1991; Tsai et al., 2009a). Awareness involves the practice of mindfulness, and in particular, the noticing of emotions within oneself and in others (Tsai et al., 2009b). Courage refers to engaging in vulnerable self-disclosures and practicing boundaried support. Love encompasses healthy caring for oneself and others, and in particular, responding affirmingly to another person's self-disclosures.
Study: NCT05944224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH4336
Description: SPH4336 Tablets ：Orally, 400mg once a day ; 28 days/cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH4336
Description: SPH4336 Tablets ：Orally, 400mg once a day ; 28 days/cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Intravenous infusion, 6mg/Kg,28 days/cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Intravenous infusion, 6mg/Kg,28 days/cycle
Study: NCT05894239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Participants will receive an inavolisib tablet to be taken orally (PO), once a day (QD), on Days 1-21 of each 21-day cycle, beginning on Day (D) 1 of Cycle (C) 1 of maintenance treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Phesgo
Description: Phesgo will be administered to participants subcutaneously every 3 weeks (Q3W) on D1 of each 21-day cycle.
Study: NCT05755854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic γ9δ2 T Cells
Description: dose escalation (3+3) : dose 1 (5 × 10\^7cells/kg) ,dose 2 (1 × 10\^8 cells/kg) ,dose 3 (2 × 10\^8cells/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous fludarabine on days-5 and -4,the infusion dose is adjusted according to the subject's condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous cyclophosphamide on days -5、-4、and -3, the infusion dose is adjusted according to the subject's condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoredronic acid
Description: Intravenous zoredronic acid 50ug/kg 24 hours before cell infusion（or according to the dosage of the instruction）（If applicable）
Study: NCT06465979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Manipulation
Description: The acoustic properties of speech sounds will be modified in two main ways. The first way is to introduce gradual changes to the perceived articulation of the target speech sound, such as changing from sh to s by various types of signal processing and filtering. The second type of change is to modify acoustic properties of the sounds that immediately precede the target speech sound, such as changing the speaking rate or its frequencies composition.
Study: NCT06242665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low UPF Nutritional Guidance
Description: Self-guided instructions from study team.
Study: NCT05841160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam Hydrochloride
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam Hydrochloride
Description: oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: oral tablet
Study: NCT06242665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low UPF Snacks (Study Provided)
Description: Low UPF snacks provided to participant
Study: NCT05841160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study: NCT05490069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iCBT-based EMI
Description: Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and real-time chat-based support messages, delivered according to participants' preferences.
Study: NCT06036979

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral plane block
Description: With the patients are placed in the sitting position, counting down from C7 spinous process, a high frequency linear ultrasound probe is placed on the spinous process in the parasagittal plane at T5 level and then is slided laterally 2-3 cm to make the transverse processes clearly visualized . Under aseptic conditions, a 22-gauge block needle (50mm, B.Braun, Germany) is inserted using in-plane technique toward the paravertebral space, immediately above the pleura and below the superior costotransverse ligament. The position of the needle is confirmed by the descent of the pleura when injecting 2 to 3 ml of saline solution for hydrolocalization. Then 0.3ml/kg of bupivacaine 0.25% is injected under ultrasound guidance. Block success is defined as reduced sensitivity to cold and pinprick stimuli as compared with the contralateral side 20 minutes after local anesthetic injection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: With the patients are placed in the sitting position, counting down from C7 spinous process, a high frequency linear ultrasound probe is placed on the spinous process in the parasagittal plane at T5 level and then is slided laterally 2-3 cm to make the tips of the transverse processes clearly visualized . The following muscles seen from superficial to deep layer are trapezius, rhomboid major and erector spinae muscles. Under aseptic conditions, a 22-gauge block needle (50mm, B.Braun, Germany) is inserted using in-plane technique to reach the interfascial plane between the transverse process and the erector spinae muscle. Following confirmation of the accurate position of the needle tip with 3-5 ml normal saline solution, 0.3ml/kg of bupivacaine 0.25% is injected under ultrasound guidance. Block success is defined as reduced sensitivity to cold and pinprick stimuli as compared with the contralateral side 20 minutes after local anesthetic injection.

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous morphine, ketorlac and paracetamol
Description: • In the control group only we add 10mg intravenous morphine, 30 mg intravenous ketorlac and 1 gm intravenous paracetamol for analgesia.
Study: NCT06168721

Intervention type: OTHER
Intervention: Expert survey
Description: The expert group will participate in a two-round survey using the Delphi method. The first round aims to assess the relevance of the proposed ICF categories and to identify missing concepts. The second round will aim to confirm the appropriateness of including the selected categories in the ICF core set. Each round will last 3 weeks and the experts will be provided with feedback on the results obtained.
Study: NCT06472505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: polyglycolic acid(Neoveil)
Description: This study plans to enroll patients with pituitary tumors who need to undergo surgical treatment according to current routine medical standards. After the tumor tissue is removed, the integrity of the spider web or skull base will be thoroughly checked by endoscopy during the operation to confirm whether there is any cerebrospinal fluid leakage. At the end of the operation, use a 100\*50\*0.15mm, green sheet-like Navi tissue repair patch, cut it aseptically to fit the size of the defect for repair (the common case is 2\*3.5cm defect), and place it on the spider web or skull base Tissue repair at the surgical site to prevent cerebrospinal fluid leakage.
Study: NCT04104477

Intervention type: OTHER
Intervention: Range of Motion Tasks
Description: Participants will perform range of motion (thumb only) to evaluate fine and gross motor function.
Study: NCT04652063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Medicine
Description: Osteopathic evaluation and treatment (gentle touch according to published protocols) will take about 15 - 20 minutes, and will be performed every 7 - 10 days during the infant's NICU stay once they reach at minimum of at least 28 weeks corrected gestational age and until they reach 36 weeks corrected gestational age.
Study: NCT06190210

Intervention type: DIAGNOSTIC_TEST
Intervention: electroencephalography
Description: Pre-, per- and postoperative electroencephalography

Intervention type: DIAGNOSTIC_TEST
Intervention: Near-Infrared Spectroscopy
Description: Pre-, Per- and Postoperative near-infrared spectroscopy returning regional cerebral oxygen saturation

Intervention type: DIAGNOSTIC_TEST
Intervention: neuronal cell-free DNA
Description: CfDNA which is characterized based on methylation patterns to determine the tissue of origin
Study: NCT05420519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70 CAR-T cells
Description: Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
Study: NCT05295524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kaftrio utilization in real life
Description: daily utilization of PHEAL-CR-K application at home and VOC (volatile organic compound) measure of exhaled air for a group of the patients
Study: NCT06076109

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prone position
Description: Patients who require supplemental oxygen through a non-invasive device (nasal cannulas or reservoir mask) in the prone position.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: Patients who require supplemental oxygen through a non-invasive device (nasal cannulas or reservoir mask) in the supine position with the head of the bed between 30-60º.